DAVIS, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio”), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, today released a letter to shareholders from Chief Executive Officer, Kevin Helash.

See more here:
Marrone Bio Innovations Issues Shareholder Letter

The access information for the investor conference call is as follows: Domestic US/Canada - 1-(866) 342-8588Direct Toll / International - 1-(203) 518-9865 Program Title: Generex Biotechnology Conference Call Conference ID – 61174

More:
Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Friday February 5, 2021 at 9:00 AM

Alliance for Regenerative Medicine Responds to EU Beating Cancer Plan

Go here to read the rest:
Alliance for Regenerative Medicine Responds to EU Beating Cancer Plan

San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced that members of its leadership team will present at several upcoming investment events in February, including the Small-Cap Growth Investor Conference, the Money Show February Virtual Expo, and the Benzinga Cannabis Capital Conference taking place virtually.

Read more here:
Skye Bioscience to Participate in Investment Conferences in February

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

Originally posted here:
Red Light Holland Announces Increase in Bought Deal Equity Financing to $10 Million

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

See the rest here:
Medexus Announces Upsize to Previously Announced Bought Deal Public Offering

WOBURN, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced the closing of its previously announced underwritten public offering of 1,040,000 shares of its common stock at a public offering price of $12.25 per share. Gross proceeds before deducting underwriting discounts and commissions and other offering expenses are approximately $12.7 million. Existing investors, including shareholder Jack W. Schuler, as well as institutional and retail investors participated in the offering.

Read more here:
Yield10 Bioscience Announces Closing of $12.7 Million Public Offering

LAKE FOREST, Ill., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that its subsidiary Assertio Therapeutics, Inc. (“Assertio Therapeutics”) entered into a Confidential Settlement Agreement and Mutual Release (the “Settlement Agreement”) with its primary product liability insurer, Navigators Specialty Insurance Company and Navigators Insurance Company (“Navigators”).

See the article here:
Assertio Announces $5.0 Million Insurance Settlement and General Corporate Updates

REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced the appointment of Esther Martinborough, Ph.D., to its board of directors, expanding its membership to ten directors.

Read this article:
Codexis Appoints Dr. Esther Martinborough to its Board of Directors

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in February:

Read more:
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, and the executive management team will participate in a fireside chat at the Guggenheim Healthcare Talks | 2021 Oncology Days on February 11, 2021, at 2:30 p.m. EST.

Here is the original post:
Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days

TORONTO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to announce that its Co-founder and CEO, Jody Aufrichtig will be presenting at the Canaccord Genuity conference "New Paradigms & Treatment Approaches in Mental Health", being held tomorrow, February 4, 2021 at 9am EST.

Read more:
Psyence Group Presenting at Canaccord Genuity Conference "New Paradigms & Treatment Approaches in Mental Health"

BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at the public offering price of $16.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Landos Biopharma. All of the shares of the common stock are being offered by Landos Biopharma.

Read more from the original source:
Landos Biopharma Announces Pricing of Initial Public Offering

With her sun-kissed hair and flawless golden skin, it's easy to forget that Heidi Klum is in her mid 40s. Genetics certainly help. But so do Heidi Klum's favourite skincare products by Glossier and Drunk Elephant, plus a reminder of home courtesy of German beauty brand The Cream by Augustinus Bader.

In a rare selfie, Klum showed off the Perfectil Hair Skin And Nails Vitamins she takes daily, alongside this smorgasbord of beauty products, which proves the supermodel takes her skincare seriously.

Here are some of her favourite products:

More from womanandhome:

Drunk Elephant T.L.C. Framboos Glycolic Resurfacing Night Serum

This night serum contains a hefty dose of glycol acid to exfoliate built-up dead skin cells and resurface dull, uneven skin. Expect brighter, smoother skin when you wake.

Drunk Elephant T.L.C. Sukari Babyfacial 25% AHA + 2% BHA Mask

If you like to feel a product working, you'll positive love this mask. Like an AHA/BHA facial in a bottle, it resurfaces skin to reveal greater clarity and improved skin tone.

Drunk Elephant C-Firma Day Serum

This vitamin C day serum is packed with antioxidants to protect skin from urban aggressors.

Glossier Solution

A liquid exfoliator that you apply a bit like toner, it buffs away dead dulling skin with a single swipe.

Mario Badescu Drying Lotion

We know, we know, even supermodels get spots. This cult zit lotion contains salicylic acid, sulfur, and zinc oxide to dry up blemishes - fast.

Augustinus Bader The Rich Cream

The brainchild of a stem cell scientist no less, this overnight treatment uses amino acids and vitamins to re-energise cells to repair damage more effectively.

Visit link:
Heidi Klum loves to pamper her skin with goodies from Drunk Elephant and Glossier - Woman & Home

CHICAGO, Feb. 2, 2021 /PRNewswire/ -- Paragon Biosciences, a life science innovator that creates, invests in and builds life science companies in biopharmaceuticals, cell and gene therapy and synthetic biology utilizing artificial intelligence, today announced the launch of CiRC Biosciences, a cell therapy company developing treatments for serious diseases with high, unmet needs with an initial focus on the eye.

"The addition of CiRC Biosciences to our portfolio builds upon our cell and gene therapy platform, an area that has tremendous potential to address serious genetic diseases," said Jeff Aronin, founder, chairman and chief executive officer of Paragon Biosciences. "CiRC Biosciences gives us the science to target retinal diseases that could lead to vision restoration with numerous other applications in the years ahead."

CiRC Biosciences is currently advancing pre-clinical development of chemically induced retinal cells for vision restoration in Geographic Atrophy Age-Related Macular Degeneration (Dry AMD), which is the most common cause of irreversible vision loss over the age of 65, and advanced Retinitis Pigmentosa (RP), a genetic disorder that causes tunnel vision and eventual blindness. There are no U.S. Food & Drug Administration (FDA) approved treatments to restore vision loss in Dry AMD or RP.

The company's novel mechanism of action is designed for direct chemical conversion of fibroblasts into other cell types using a cocktail of small molecules in an 11-day chemical conversion process. Pre-clinical studies have shown efficacy in blind mice that demonstrated vision restoration. CiRC Biosciences has provisional patent applications to protect its platform.

"Our technology transforms ordinary skin cells into specialized retinal cells using a cocktail of small molecules," said Sai Chavala, M.D., co-founder and chief scientific officer of CiRC Biosciences. "This process is potentially safer, quicker, more cost effective and easier to manufacturer than using traditional stem cells. Working with Paragon Biosciences to build and advance CiRC Biosciences provides us the opportunity to efficiently progress this technology through research and development stages.

CiRC Biosciences first reported its discovery in the highly respected scientific journal Nature (April 15, 2020). A recently published New England Journal of Medicine article (Nov. 5, 2020)discussed CiRC's technology of using chemically induced cells to restore retinal function. The article concluded, "The new and emerging strategies for the rescue, regeneration, and replacement of photoreceptors suggest a bright future in the fight to preserve and restore vision in blinding eye diseases."

The abstract in Nature is available here: https://www.nature.com/articles/s41586-020-2201-4

Access to the NEJM article is available here: https://www.nejm.org/doi/full/10.1056/NEJMcibr2027602

About CiRC Biosciences CiRC Biosciences is a privately held cell therapy company dedicated to developing treatments for serious diseases with high, unmet needs with an initial focus on the eye. Currently it is pre-clinical phase for Geographic Atrophy Age-Related Macular Degeneration (Dry AMD) and advanced Retinitis Pigmentosa (RP). CiRC Biosciences is a portfolio company of Paragon Biosciences. Visit our website: https://circbiosciences.com/.

About Paragon Biosciences Paragon is a life science innovator that creates, invests in and builds life science companies in biopharmaceuticals, cell and gene therapy and synthetic biology utilizing artificial intelligence. The company's current portfolio includes Castle Creek Biosciences, CiRC Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies created and supported by the replicable Paragon Innovation Capital model. Paragon stands at the intersection of human need, life science, and company creation. For more information, please visit https://paragonbiosci.com/.

Media Contact:

Evelyn M. O'Connor Paragon Biosciences 312-847-1335 [emailprotected]

SOURCE Paragon Biosciences

Home

Read the original:
Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform - PRNewswire

Pet Industry Veteran Brings Track Record of Success Pet Industry Veteran Brings Track Record of Success

Read more:
Better Choice Company Announces Ryan Wilson Vice President of Marketing

FREMONT, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that early onset of action data for Qtrypta™, Zosano’s investigational therapy for the acute treatment of migraine formulated utilizing its microneedle system, were presented at the Annual Headache Cooperative of the Pacific Winter Conference.

Continue reading here:
Zosano Pharma Presents Early-Onset of Action Data for Qtrypta™ in Acute Treatment of Migraines

FURTHER UPDATE ON USAMRIID CHALLENGE AND ADDITIONAL EUROPEAN PATENT GRANTED FOR VAXIL’S ANTICANCER ANTIBODY PLATFORM

View post:
Vaxil Appoints a Special Advisor to the Board of Directors

New York, NY and Mainz, Germany, February 1, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that preclinical data in non-human primate and mouse models from Pfizer and BioNTech’s mRNA-based vaccine candidates, BNT162b1 and BNT162b2, for the prevention of COVID-19 were published in the journal Nature. Some of these data were initially made available to the public on September 9, 2020 via the online preprint server, bioRxiv. For additional details, please read the previously issued press release.

Read more from the original source:
Pfizer and BioNTech Publish Preclinical Data from Investigational COVID-19 Vaccine Program in Nature

Pivotal IDE Study will evaluate SetPoint’s proprietary bioelectronic device for treatment of Rheumatoid Arthritis Pivotal IDE Study will evalute SetPoint’s propriertary bioelectronic device for treatment of Rheumatoid Arthritis

Continued here:
SetPoint Medical Announces First Patient Enrolled in the RESET-RA Study